Recommendations for initiating use of afrezza inhaled insulin in individuals with type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 20, Issue 6, 2018, Pages 448-451

  Pettus, Jeremy ^a   Santos Cavaiola, Tricia ^a   Edelman, Steven V ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Continuous glucose monitoring; Hypoglycemia; Inhaled insulin; Rapid acting insulin; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT;

CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG DOSE TITRATION; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LEARNING; PERSONAL EXPERIENCE; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REVIEW; ANALYSIS; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, SHORT-ACTING;

EID: 85048874425     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2017.0463     Document Type: Review

References (15)

1. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14: 750-756.
2. Group UKHS. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147.
3. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38: 971-978.
4. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202.
5. Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol 2015;52:845-853.
6. Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab 2015;41:116-125.
7. Smith CB, Choudhary P, Pernet A, et al. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009;32:1196-1198.
8. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15.
9. Haugstvedt A, Wentzel-Larsen T, Graue M, et al. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med 2010;27:72-78.
10. MKC-TI-171. Trial 171: a Phase 3, Multicenter, Open-Label, Randomized, Forced-Titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere-Insulin Inhalation Powder in Combination with a Basal Insulin Versus Insulin Aspart in Combination with a Basal Insulin in Subjects with Type 1 Diabetes Mellitus Over a 24-Week Treatment Period. 2013. Clinical Trials.gov identifier NCT01445951. https:// clinicaltrials.gov ct2/show/NCT01445951?term = NCT014459 51&rank = 1 (accessed March 30, 2017).
11. Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 2015;38:2266-2273.
12. AFREZZA [package insert]. MannKind Corporation. Danbury, CT; 2017. https://afrezza.com/wp-content/uploads/2016/ 08/afrezza.pdf (accessed October 7, 2017).
13. Heinemann L, Parkin CG. Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res 2018; article ID4568903, 9 pp.
14. Heinemann L, Baughman R, Boss A, Hompesch M. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol 2017;11:148-156.
15. Visentin R, Giegerich C, Jager R, et al. Improving efficacy of inhaled technosphere insulin (Afrezza) by postmeal dosing: in-silico clinical trial with the University of Virginia/ Padova type 1 diabetes simulator. Diabetes Technol Ther 2016;18:574-585.